[Early Systemic Administration of IL-10 Inhibits Neuropathic Pain in Adult Rats with Tibial Nerve Injury]

Area of Science:

• Neuroscience
• Pain Research
• Pharmacology

Background:

• Peripheral neuropathic pain is a debilitating condition.
• The modified spared nerve injury (mSNI) model in rats is used to study neuropathic pain.
• Interleukin-10 (IL-10) is an immunomodulatory cytokine with potential anti-inflammatory effects.

Purpose of the Study:

• To investigate the therapeutic effect of early systemic Interleukin-10 (IL-10) administration on peripheral neuropathic pain.
• To evaluate the impact of IL-10 on pain behaviors induced by modified spared nerve injury (mSNI) in a rat model.

Main Methods:

• Adult male Sprague-Dawley rats underwent mSNI or sham surgery.
• Rats were randomly assigned to receive intraperitoneal injections of IL-10 or phosphate-buffered saline (PBS).
• Pain responses were assessed using mechanical (von Frey, pinprick) and thermal (acetone) stimuli on ipsilateral and contralateral hindpaws.

Main Results:

• The mSNI model successfully induced region-specific neuropathic pain, characterized by allodynia and hyperalgesia.
• Early systemic administration of IL-10 significantly attenuated both allodynia and hyperalgesia in mSNI rats compared to PBS-treated controls.
• These pain-relieving effects of IL-10 were persistent.

Conclusions:

• The mSNI model is a valid and useful tool for studying peripheral neuropathic pain in rodents.
• Early systemic IL-10 administration effectively inhibits the development of neuropathic pain following tibial nerve injury.